Clinical Efficacy of R-EDOCH Protocol in the Treatment of Newly Diagnosed Double Expression Lymphoma.
10.19746/j.cnki.issn.1009-2137.2019.04.023
- Author:
Xu-Yan ZHANG
1
;
Can HUANG
1
;
Dian-Wen WANG
1
;
Ling-Li ZOU
1
;
Chuan-Qing TU
2
Author Information
1. Department of Hematology, Baoan Hospital Affiliated to Southern Medical University, Shenzhen, 510060, Guangdong Province, China.
2. Department of Hematology, Baoan Hospital Affiliated to Southern Medical University, Shenzhen, 510060, Guangdong Province, China,E-mail: sztcq@126.com.
- Publication Type:Journal Article
- MeSH:
Hematopoietic Stem Cell Transplantation;
Humans;
Lymphoma, Large B-Cell, Diffuse;
Retrospective Studies;
Transplantation, Autologous;
Treatment Outcome
- From:
Journal of Experimental Hematology
2019;27(4):1138-1142
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical efficacy of R-EDOCH protocol in the treatment of newly diagnosed double expression lymphoma.
METHODS:The clinical data of 51 patients with newly diagnosed double expression lymphoma treated by R-EDOCH protocol were retrospectively analyzed in the period from May 2012 to October 2017, then overall remission rate (ORR), disease control rate (DCR), progression-free survival (PFS) rate and total survival (OS) rate were evaluated; moreover the patients were grouped according to IPI score and whether accepting hematopoietic stem cell transplantation(HSCT) and the clinical efficacy was compared.
RESULTS:The ORR was 96.08% (49/51) and DCR was 100.00% (51/51) in all patients. Six cases out of 51 patients (11.76%) relapsed and progressed during the followed-up. The followed-up showed that 2 year-PFS rate and OS rate were 84.31% (43/51) and 94.12% (48/51) respectively. The ORR, SD rate, 2 year-PFS rate and OS rate in the patients with IPI 0-2 and 3-5 scores were no statistically different(p>0.05); the 2 year-PFS and OS rates between patients in subgroup of IPI 0-2 and 3-5 scores also were not statistically different (p>0.05), no matter whether the patients received auto-HSCT or not. The comparison of 2 year-PFS and OS rates in auto-HSCT patients and non-auto-HSCT patients showed no statistical difference(p>0.05).
CONCLUSION:The R-EDOCH protocol in treatment of newly diagnosed double expression lymphoma possess the good overall clinical efficacy, the combination of R-EDOCH with auto-HSCT displays ascending trend of PFS.
